Anavar (Oxandrolone): A Complete Research Guide

Oxandrolone, marketed historically under the trade name Anavar, is one of the most extensively studied oral anabolic-androgenic steroids (AAS) in the clinical literature. First synthesized by Searle Laboratories in 1962, it has appeared in human trials addressing burn recovery, HIV-associated wasting, alcoholic hepatitis, Turner syndrome, and constitutional growth delay in pediatric populations. Among 17α-alkylated orals, it is consistently characterized in published studies as having a comparatively favorable hepatic and androgenic profile, which makes it a frequent reference compound in research contexts.

Chemistry and Structural Basis

Oxandrolone is a synthetic derivative of dihydrotestosterone (DHT). Its IUPAC designation is (1S,3aS,3bR,5aS,9aS,9bS,11aS)-1-hydroxy-1,9a,11a-trimethylhexadecahydro-7H-indeno[5,4-f]chromen-7-one, with molecular formula C₁₉H₃₀O₃ and molecular weight of approximately 306.4 g/mol. The defining structural modification is the substitution of the carbon-2 atom in the A-ring of the DHT skeleton with an oxygen atom, producing a heterocyclic lactone ring. This single change is the basis for most of the compound's reported pharmacological behavior.

A second modification — 17α-methylation — is shared with most orally bioavailable AAS. The methyl group at C-17 prevents rapid first-pass hepatic deactivation, allowing meaningful serum concentrations after oral administration. As with all 17α-alkylated compounds, this modification is the structural feature most commonly associated with hepatic stress in the published literature.

The combination of a DHT base, the C-2 oxygen substitution, and the C-17α methyl group results in a molecule that is non-aromatizable (it cannot be converted to estradiol by aromatase) and that demonstrates a relatively high anabolic-to-androgenic ratio in animal bioassays. The Hershberger assay values commonly cited for oxandrolone — roughly 322–630 anabolic to 24 androgenic, relative to a methyltestosterone reference of 100/100 — originate from rodent work conducted in the 1960s and have been reproduced in subsequent reviews. Researchers should note that animal bioassay ratios do not translate directly to human clinical effects.

Mechanism of Action

Oxandrolone binds the androgen receptor (AR) with affinity reported in the literature as roughly one-third that of testosterone, but with prolonged receptor occupancy attributed in part to its resistance to 5α-reductase metabolism (the compound is already a DHT derivative and cannot be reduced further at the same site). Following AR binding, the receptor-ligand complex translocates to the nucleus and modulates transcription of androgen-responsive genes, with downstream effects on muscle protein synthesis, nitrogen retention, and erythropoiesis.

Several mechanisms have been proposed to account for the compound's reported clinical effects beyond direct AR agonism:

• Upregulation of intracellular amino acid transport, observed in the 1995 Sheffield-Moore et al. work in burn-injured patients.
• Modest increases in IGF-1 and IGF-binding protein-3 reported in pediatric Turner syndrome trials.
• A documented effect on lipolysis in subcutaneous adipose tissue, described in studies on HIV-associated lipodystrophy populations.

Because oxandrolone does not aromatize, estrogenic side effects (gynecomastia, water retention from estradiol) are not a feature of the compound's profile in the clinical literature. Progesterone receptor activity is also negligible. The reported side-effect profile is therefore dominated by androgenic, hepatic, and cardiovascular endpoints rather than estrogenic ones.

Why It Is Considered Milder Than Most 17α-Alkylated Orals

The "mild" characterization of oxandrolone in the AAS literature rests on three reasonably well-documented observations.

First, hepatic strain markers tend to rise less steeply with oxandrolone than with comparator orals such as methyltestosterone, stanozolol, or methandrostenolone at equivalent androgenic doses. The 1999 Pan et al. and subsequent burn-recovery trials reported transaminase elevations that, while present, were generally smaller in magnitude and more readily reversible after discontinuation than those reported with other 17α-alkylated comparators. The compound is partially excreted unchanged in urine, which is unusual for an oral AAS and is hypothesized to reduce the relative hepatic metabolic burden.

Second, the androgenic-to-anabolic ratio measured in animal models is shifted toward the anabolic end. In practice, this is reflected in lower reported rates of androgenic side effects (acne, accelerated male-pattern hair loss, prostate complaints) at therapeutic doses, though these effects are still present and dose-dependent.

Third, the absence of aromatization removes an entire class of side effects from the profile. Researchers studying physique-related endpoints have reported that subjects do not retain subcutaneous water in a manner comparable to aromatizable compounds, which is the basis for the compound's frequent appearance in cutting-phase research protocols.

These observations should not be read as a claim of safety. Hepatic, lipid, and HPG-axis suppression effects are well-documented and are addressed in subsequent sections.

Dose Ranges Reported in the Literature

Clinical doses for oxandrolone in published human trials span a wide range depending on indication. In adult burn-recovery studies, daily doses of 20 mg (typically split as 10 mg twice daily) have been the most frequently studied and have shown improvements in lean body mass and wound healing endpoints. HIV-wasting trials have used 20–40 mg per day. Pediatric Turner syndrome and constitutional growth delay protocols use substantially lower doses, typically 0.05–0.1 mg/kg/day.

In the broader research literature concerning physique-oriented use in adult males, reported dose ranges are generally higher than the clinical indications above. Commonly cited ranges in survey and review articles span 20–80 mg per day, with split dosing (AM and PM) frequently described. The plasma half-life of oxandrolone is reported at approximately 9–10 hours, which is the pharmacokinetic basis for the split-dose convention — it maintains more stable serum concentrations across a 24-hour period than once-daily administration.

Researchers should note that dose-response data above the 40 mg/day range in adult male research subjects is sparse in the peer-reviewed literature; most controlled human work has been conducted at clinical doses. Reports of higher doses derive primarily from observational and self-report sources, which carry significant methodological limitations.

Female-Use Literature and Virilization Risk

Oxandrolone occupies a distinct position in the AAS literature with respect to female research populations. It is the compound most extensively studied in adult female and pediatric female populations, having been used in Turner syndrome protocols since the 1980s. The 2011 Gault et al. randomized controlled trial in Turner syndrome girls is among the more frequently cited references, reporting modest height gains with low-dose oxandrolone (0.03–0.05 mg/kg/day) without clinically significant virilization at the doses studied.

In the broader literature on female AAS use, oxandrolone is consistently described as having the lowest reported incidence of virilization (voice deepening, clitoromegaly, hirsutism, menstrual disruption) among commonly studied compounds at comparable anabolic doses. The reported threshold above which virilization signs appear with measurable frequency in adult female subjects is generally placed in the 10–20 mg/day range, though individual variation is substantial and some signs — particularly voice changes — are partially or fully irreversible once established.

The female-use literature emphasizes several points worth flagging:

• Voice changes are mediated by androgenic effects on the laryngeal cartilage and are not reversed by discontinuation.
• Menstrual irregularity is reported but is typically reversible after cessation in studies that followed subjects post-cycle.
• Clitoral enlargement at low doses is uncommon but reported, and is not consistently reversible.

The "lowest virilization risk" characterization is relative — not absolute. No AAS is virilization-free in female subjects at supraphysiologic doses.

Lipid Panel Impact

The cardiovascular signal most consistently reported in oxandrolone trials is an unfavorable shift in the lipid profile, specifically a reduction in HDL-cholesterol and a less consistent rise in LDL-cholesterol. The 2010 Hartgens and Kuipers review summarized prior trial data showing HDL reductions in the 30–50% range from baseline at therapeutic adult doses, with some studies reporting larger reductions. The mechanism involves induction of hepatic lipase, an enzyme that catabolizes HDL particles.

Several considerations are noted in the literature:

• HDL suppression with oral AAS is generally more pronounced than with injectable testosterone esters at comparable androgenic dose, attributed to the higher first-pass hepatic concentrations that orals produce.
• The lipid effect is dose-dependent and largely reversible within 4–8 weeks of discontinuation in most reported subjects.
• Markers of endothelial function and arterial stiffness have shown adverse changes in some controlled studies, though long-term cardiovascular event data specific to oxandrolone is limited.

Hepatic markers (ALT, AST, GGT, and less commonly bilirubin) typically show modest elevations during oxandrolone administration. Cholestatic patterns, which are well-documented with some other 17α-alkylated compounds, are reported less frequently with oxandrolone but are not absent from the case literature.

Cycle Length and HPG-Axis Considerations

Research protocols involving oxandrolone in adult male subjects most commonly describe cycle lengths in the range of 6–8 weeks. The rationale offered in the literature combines hepatic recovery considerations, the diminishing returns of receptor downregulation with prolonged exposure, and the degree of HPG-axis suppression observed at progressively longer durations.

Suppression of endogenous testosterone production has been documented with oxandrolone monotherapy at moderate doses. The 2006 study by Friedl et al. and subsequent work reported reductions in serum LH and total testosterone within the first two weeks of administration, with the magnitude of suppression generally less than that observed with comparable doses of injectable testosterone but still clinically meaningful. Recovery of HPG-axis function after discontinuation has been variable across studies, with most subjects returning toward baseline within 4–12 weeks, though slower recovery has been reported in some individuals and after longer exposure.

Post-cycle therapy (PCT) protocols described in the research literature for oxandrolone-only cycles typically involve selective estrogen receptor modulators — most commonly tamoxifen or clomiphene — used for several weeks following the final dose. The specific protocols vary substantially across sources, and controlled comparative data on PCT regimens specifically following oxandrolone monotherapy is limited; most published PCT data concerns higher-suppression compounds.

Open Questions

Several aspects of the oxandrolone literature remain underdeveloped and warrant flagging for researchers planning protocols.

The long-term cardiovascular consequences of repeated oxandrolone exposure — particularly cumulative effects on endothelial function and atherosclerotic progression — have not been characterized in prospective, long-duration human trials. Most cardiovascular data is short-term and based on surrogate markers rather than hard endpoints.

Dose-response data above 40 mg/day in adult research subjects is largely absent from the controlled literature, despite frequent reference to higher doses in observational and survey work. Whether the relatively favorable hepatic profile observed at clinical doses scales linearly, sub-linearly, or non-linearly to higher exposures is not well-established.

The female-use literature, while more developed than for most AAS, is concentrated in pediatric Turner syndrome protocols and in burn-recovery contexts. Adult female physique-research dose-response and virilization-threshold data is comparatively sparse and would benefit from controlled investigation.

Finally, the interaction of oxandrolone with newer compounds appearing in the research-peptide and SARM literature — including potential additive effects on lipid panels and HPG suppression when stacked with compounds such as MK-677 or various GHRP/GHRH analogs — has not been systematically studied. Researchers combining oxandrolone with adjunct compounds should treat the resulting profile as uncharacterized rather than additive in a predictable way.